PaulHaluskaJr.MD

PubMed

• 16 citations
  Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
  Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska
  NPJ Breast Cancer. 2021-10-05
• 1 citations
  Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
  Joleen M. Hubbard, Jun Yin, Erin L. Schenk, Rui Qin, Joel M. Reid
  Investigational New Drugs. 2021-09-13
• 21 citations
  Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
  Rachel M. Hurley, Cordelia D. McGehee, Ksenija Nesic, Cristina Correia, Taylor M. Weiskittel
  NAR Cancer. 2021-07-02

Journal Articles

• Phase 1b Study of Safety, Tolerability and Efficacy of R1507, a Monoclonal Antibody to Igf-1r in Combination with Multiple Standard Oncology Regimens in Patients with ...  
  Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJE, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R, Cancer Chemother Pharmacol, 3/1/2014
• Low Expression of Insulin-Like Growth Factor Binding Proteins Predicts Poor Outcomes in Ovarian Cancer Patients  
  Glaser G, Haluska P, Harrington SC, Farzan T, Winterhoff BJ, Goodman KM, Kalli KR, Konecny GE, Gynecologic Oncology, 1/1/2013
• Multifocal Neuropathy as the Presenting Symptom of Purkinje Cell Cytoplasmic Autoantibody-1  
  Bradshaw MJ, Haluska P, Mckeon A, Klein CJ, Muscle Nerve, 1/1/2013
• Insulin-like Growth Factor Pathway-targeted Therapy in Breast Cancer  
  Sirop SJ, Haluska P, Current Breast Cancer Reports, 1/1/2011
• Insulin Receptor A and IGF-IR in AML-Response  
  Wahner-Hendrickson AE, Haluska P, Erlichman C, Gottardis M, Carboni JE, Karp JE, Kaufmann SH, Cancer Res, 9/1/2010
• Cixutumumab  
  McKian KP, Haluska P, Expert Opin Investig Drugs, 7/1/2009
• Clinical Evaluation of Sequential Topoisomerase Targeting in the Treatment of Advanced Malignancy  
  Gupta E, Toppmeyer D, Zamek R, Much J, Ibrahim N, Goodin S, Kane M, Aisner J, Li X-G, Haluska P, Medina M, Cornfield A, Vyas V, Natelson E, Giovanella B, Saleem A, Rub..., Cancer Therapeutics, 11/1/1998
• Join now to see all

Books/Book Chapters

• Hematol Oncol Clin North Am 
  Chapter: Topoisomerase-I Inhibitors in Gynecologic Tumors 
  Page 43 - 61Haluska P, Rubin E, Verschraegen CF1999
• Adv Enzyme Regul 
  Chapter: A Role for the Amino Terminus of Human Topoisomerase I 
  Page 253 - 262Haluska P, Rubin EH1998
• Ann N Y Acad Sci 
  Chapter: Identification of Topoisomerase I Mutations Affecting Both DNA Cleavage and Interaction with Camptothecin 
  Page 111 - 127Li X-G, Haluska P, Hsiang YH, Bharti A, Kufe DW, Rubin EH1996

Abstracts/Posters

• Novel Strategies to Target the C5 Subclass of High-grade Serous Ovarian Cancer Using Patient-derived Xenografts
  Haluska P, 15th Biennial Meeting of the International Gynecologic Cancer Society, Melbourne, Australia, 11/1/2014
• Randomized Phase II Trial of Capecitabine and Lapatinib +/- IMC-A12 in Patients with HER2+ Breast Cancer Previously Treated Iwth Trastuzumab and an Anthracycline And/o...
  Haluska P, ASCO Annual Meeting, Chicago, Illinois, 6/1/2014
• Overexpression of IGF-2 in Primary Patient Ovarian Cancer Tumorgrafts Increases Bowel and Thoracic Metastasis
  Haluska P, AACR Annual Meeting, San Diego, California, 4/1/2014
• Utilizing ER Target Genes as Biomarkers of Endocrine Response in Serous Ovarian Carcinoma
  Haluska P, AACR Annual Meeting, San Diego, California, 4/1/2014
• Phase I Dose-escalation and Drug Interaction Study of Abt-888 (Parp1 Inhibitor) And Topotecan (Topoisomerase I Inhibitor) In Patients with Advanced Cancer
  Boakye-Agyeman F, Reid J, Menefee M, Buhrow S, Walden C, Piens J, Kayode O, Erlichman C, Haluska P, Northfelt DW, Kaufmann SH, Ames M, Satele DV, Tang H, Peethambaram ..., Clin Pharmacol Ther, 3/1/2014
• The Development and Characterization of Ovarian Cancer Bowel Metastases in Individual Patient Tumorgraft Models
  Butler A, Becker M, Weroha S, Enderica-Gonzalez S, Harrington S, Hou X, Haluska P, Gynecol Oncol, 10/1/2013
• In Vivo Antitumor Activity of the PARP Inhibitor Niraparib (MK-4827) In Homologous Recombination Deficient and Proficient Ovarian Cancer
  Haluska P, AACR Advances in Ovarian Cancer Research, Miami, Florida, 9/1/2013
• Intraperitoneal (ip) Administration of an Oncolytic Measles Virus (mv) Strain Expressing the Sodium Iodine Symporter Gene in Patients (pts) With Advanced Ovarian Cance...
  Galanis E, Atherton P, Dowdy S, Cliby W, Haluska P, Long H, Aderca I, Knutson K, Block M, Federspiel M, Russell S, Peng KW, Hartmann L, Mol Ther, 6/1/2013
• Identifying Biomarkers of Estrogen Response in Models of Serous Ovarian Cancer
  Andersen CL, Sikora MJ, Haluska P, Oesterreich S, Cancer Res, 4/15/2013
• Ovarian Avatar Models Predictive of Platinum Response in Ovarian Cancer Patients
  Weroha SJ, Haluska P, Becker MA, Harrington SC, Goodman KM, Gonzalez SE, al Hilli M, Butler KA, Kalli KR, Oberg AL, Ann Oncol, 3/1/2013
• A Phase I Study of MEDI-573, and Investigational Monoclonal Antibody That Targets IGF-I and IGF-II: Safety Pharmacokinetics, and Antitumor Activity in Adults With Adva...
  Haluska P, 24th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland, 11/1/2012
• A Phase 1 Study of Medi-573, an Investigational Monoclonal Antibody That Targets IGF-I and IGF-II: Safety, Pharmacokinetics, and Antitumor Activity in Adults with Adva...
  Haluska P, Menefee ME, Plimack ER, Rosenberg JE, Northfelt DW, LaVallee T, Huang W, Yu XQ, Viner JL, LoRusso P, Eur J Cancer, 11/1/2012
• Ovarian Cancer Tumorgraft: Viral Latency Propagates Lymphoma
  Butler K, Weroha S, Becker M, Enderica-Gonzalez S, Harrington S, Hou X, Visscher D, Haluska P, Gynecol Oncol, 10/1/2012
• Ovarian Avatar Project: A Model System for Individualizing Ovarian Cancer Therapy
  Haluska P, Oberg AL, Glaser G, Gonzalez SE, Becker MA, Jacob KA, Pennil CC, Fink SR, Kalli KR, Swisher EM, Jenkins RB, Sarkaria JN, Karlan BY, Weroha SJ, Ann Oncol, 3/1/2012
• Ovarian Avatar Project: A Model System for Indivdiualizing Ovarian Cancer Therapy
  Haluska P, Targeted Anticancer Therapies (TAT), Amsterdam, Netherlands, 3/1/2012
• IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors
  Haluska P, San Antonio Breast Cancer Symposium, San Antonio, Texas, 12/1/2011
• MEDI-573--a Novel Approach to IGF-1R and IR-A Signaling Inhibition by Blocking IGF Ligands: Phase 1 PK/PD, Safety Data, and Disease Linkage Studies in Breast Cancer
  Haluska P, Huang J, Lam B, Chen X, Huang W, LoRusso P, Menefee ME, LaVallee T, Yao Y, Viner J, ASCO Breast Cancer Symposium, San Francisco, CA, 9/8/2011
• MEDI-573--a Novel Approach to IGF-1R and IR-A Signaling Inhibition by Blocking IGF Ligands: Phase I PK/PD, Safety Data, and Disease Linkage Studies in Breast Cancer
  Haluska P, ASCO Breast Cancer Symposium, San Francisco, California, 9/1/2011
• Regulation of Hormone-Resistant Breast Cancer by IGF and Insulin System Signaling
  Haluska P, Hou X, Dhar A, Yee D, Suman VJ, Harrington SC, Finckenstein F, Ingle JN, NCI Translational Science Meeting, Washington, DC, 7/28/2011
• Regulation of Hormone-resistant Breast Cancer by IGF and Insulin System Signaling
  Haluska P, NCI Translational Science Meeting 2011, Washington, District of Columbia, 7/1/2011
• Phase II Trial of the Dual IGF-1R/IR Inhibitor DMB-754807 with or without Letrozole in Aromatase Inhibitor-resisant Breast Cancer
  Haluska P, 2011 ASCO Annual Meeting, Chicago, Illinois, 6/1/2011
• Phase I Trial of Figitumumab and Pegvisomant in Patients with Advanced Solid Tumors
  Haluska PH, Dudek AZ, Bono P, Sleight B, Joensuu H, Juergens H, Pollak M, Ann Oncol, 5/1/2011
• Insulin-like Growth Factor Receptor 1 Pathway Signature Correlates with Adverse Clinical Outcome in Ovarian Cancer
  Winterhoff B, Haluska P, Kalli K, Cliby W, Gostout B, Oberg A, Maurer M, Hartmann L, Slamon D, Konecny G, Gynecol Oncol, 3/1/2011
• Combined erbB/VEGFR Blockade Has Improved Anticancer Activity over Single-pathway Inhibition in Ovarian Cancer in Vivo
  Farzan T, Harrington S, Krempski J, Weroha S, Hou X, Kalli K, Haluska P, Gynecol Oncol, 3/1/2011
• Phase I Trial of Figitumumab and Pegvisomant in Patients with Advanced Solid Tumors
  Haluska P, Targeted Anticancer Therapies, Paris, France, 3/1/2011
• Join now to see all

Lectures

• Homologous Recombination Deficiency (HRD) Score and Niraparib Efficacy in High Grade Ovarian Cancer 
  Barcelona, Spain - 11/1/2014
• Lessons Learned from Targeting the IGF-1R and Implications for Cancer Prevention 
  New Orleans, Louisiana - 10/1/2014
• The Mayo Ovarian Avatar Program: Of Mice And (Wo)men 
  Birmingham, Alabama - 10/1/2014
• Of Mice And (Wo)men: The Mayo Ovarian Avatar Project 
  Vermillion, South Dakota - 9/1/2014
• Of Mice And (Wo)men: The Ovarian Avatar Project 
  Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey - 9/1/2014
• Gynecologic Oncology 
  Amelia Island, Florida - 8/1/2014
• Chemoradiotherapy for Locally Advanced Cervical Cancer 
  Rochester, Minnesota - 7/1/2014
• Palliative Chemotherapy Approaches to Recurrent Disease and Novel Biologic Therapies 
  GYN School, Chicago, Illinois - 7/1/2014
• Role of Pharmacokinetics and Pharmacodynamics in Clinical Trials 
  Films, Switzerland - 6/1/2014
• Of Mice and (Wo)men: The Ovarian Avatar Project, Grand Rounds 
  Memorial Sloan Kettering Cancer Center, New York, New York - 5/1/2014
• The Ovarian Avatar Project: Of Mice And (Wo)men, Grand Rounds 
  Mayo Clinic in Arizona, Scottsdale, Arizona - 5/1/2014
• Ovatars: Using Patient-derived Xenografts for Selecting Best Therapies 
  Chicago, Illinois - 5/1/2014
• Novel Targeting Approaches in Ovarian Cancer 
  Chicago, Illinois - 5/1/2014
• The AVATAR Project 
  Rochester, Minnesota - 3/1/2014
• Research Seminar 
  Rochester, Minnesota - 9/1/2013
• Ovarian Avatar Models Predictive of Platinum Response in Ovarian Cancer Patients 
  Paris, France - 3/1/2013
• Systemic Therapies for Gynecological Malignancies 
  Jacksonville, Florida - 2/1/2013
• Ovarian Avatar Project 
  Mayo Clinic, Jacksonville, Florida - 2/1/2013
• Anti-IGF Ligand Antibodies 
  Santa Monica, California - 2/1/2013
• Adjuvant Therapy for Resected Ovarian Cancer 
  Kaliningrad, Russia - 10/1/2012
• Management of Metastatic Ovarian Cancer 
  Kaliningrad, Russia - 10/1/2012
• Gynecologic Cancer Case Presentations 
  Kaliningrad, Russia - 10/1/2012
• Management of Cervix Cancer 
  Kaliningrad, Russia - 10/1/2012
• Phase I Study of Figitumumab and Pegvisomant in Patients with Advanced Solid Tumors 
  Munich, Germany - 10/1/2012
• BMS-754807 
  Santa Monica, California - 2/1/2012
• Join now to see all

Other

• Ovarian Cancer 
  Mayo Clinic Radio
  9/1/2013
• Amgen Review Web-based Seminar 
  Haluska P., San Antonio Breast Cancer Symposium
  1/1/2010